#ESMO2021 Paolo A. Ascierto on the SECOMBIT: the best sequential approach with combo immunotherapy [#ipilimumab (I) /#nivolumab (N)] and combo target therapy [#encorafenib (E)/#binimetinib (B)] in patients with #BRAF mutated metastatic melanoma. Omid Hamid MD Jason Luke, MD, FACP Professor Georgina Long AO

Congrats to Immunocore for NEJM publication Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. Proud to be part of this program and its success for our patients #clinicaltrials The Angeles Clinic nejm.org/doi/full/10.10…

Thanks Oncology News Australia for this post-ESMO pod, accompanying me on my lockdown walk today, pretending to flâner dans les rues de Paris. Also highly recommend Professor Georgina Long AO episode "The OJC 49: ESMO Special 1 Early Bird Practice Changers" at oncologynews.com.au/the-ojc-49-esm…

The KRAS inhibitors familly grows : G12D mutation is targeted by MRTX1133 with convincing preclinical data on orthotopic models, in particular of pancreatic cancer. #targets21

See you all in sunny Brisbane! #COSA2022

Moving to ultra-short therapy to cure patients with cancer: a solution for sustainable cancer care. Don’t miss the editorial by Drs. Ribeiro, Dixon-Douglas and FabriceAndre that accompanies the latest issue of ESMO Open. esmoopen.com/article/S2059-…

Another #ESMObreast24...Another science productive and awarded year for BreastUnit_DMO Gustave Roussy Gustave Roussy Cancer Survivorship Group team! Barbara Pistilli Suzette delaloge Elie Rassy @JZeghondi Federica Giugliano, MD Thomas Grinda Ines Vaz Luis Julia Dixon-Douglas Fernanda Mosele Antonio Di Meglio, MD, PhD Martina Pagliuca

✨Cette année à l'#ASCO24, les médecins-chercheurs de Gustave Roussy ont participé à plus de 130 abstracts retenus par le comité scientifique du congrès, témoignant de la qualité de la recherche menée à l’Institut, et de son impact à l’échelle mondiale. #DreamTeam 🥇

✨ Gustave Roussy à l'#ASCO24 ✨ Dr Maria Alice Franzoi, oncologue médicale à Gustave Roussy, présente certains facteurs socio-economiques influencent l’adhésion à un dispositif de télésurveillance à l'ASCO. 👉 Lire le communiqué de presse : gustaveroussy.fr/fr/asco-2024-f…

Today marks the beginning of Breast Cancer Awareness Month! Thank you to all of our researchers, clinical trial participants and supporters. Without you, our clinical trials research would not be possible! #nomorelivescutshort